Perrigo announced that it has received final approval from the FDA for Calcium acetate capsules, the generic version of Fresenius Medical Care NA‘s Phoslo (calcium acetate 667mg [elemental calcium 169mg]) Gelcaps.
Calcium acetate is a phosphate regulator indicated for hyperphosphatemia in patients with end-stage renal failure on dialysis. This phosphate binder reduces the fraction of dietary phosphate absorbed by patients with end-stage renal disease by binding to dietary phosphate to form insoluble complexes that are excreted. This reduces serum phosphorous concentrations and helps prevent ectopic calcifications.
For more information call (800) 719-9260 or visit www.perrigo.com.